Bilimsel çalışmalar

Doç. Dr. Jamshid Hamdard

70 yayın. Her yayının yanında bilginin kaynağı yazar.

Profile dön

  1. Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15062406 PMID 41899326 Açık erişimli tam metinKaynak: OpenAlex

  2. Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy

    Pharmaceuticals, 2026

    DOI 10.3390/ph19040587 PMID 42075843 Açık erişimli tam metinKaynak: OpenAlex

  3. A Novel Biological Index for Predicting Neoadjuvant Treatment Response in HER2-Positive Breast Cancer: The Tumor-Immune-Proliferation-Inflammation (TIPI) Score

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15083118 PMID 42074920 Açık erişimli tam metinKaynak: OpenAlex

  4. Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer

    OncoImmunology, 2026

    DOI 10.1080/2162402x.2026.2738262 PMID 42788839 Açık erişimli tam metinKaynak: OpenAlex

  5. Predictive and Prognostic Value of Androgen Receptor Expression Across All Molecular Subtypes in Patients with Breast Cancer Who Received Neoadjuvant-Treatment: Single-Center Retrospective Analysis

    Breast Cancer Targets and Therapy, 2026

    DOI 10.2147/bctt.s647399 PMID 42936308 Açık erişimli tam metinKaynak: OpenAlex

  6. Real-world Efficacy and Safety of Trastuzumab Deruxtecan in HER2-positive Metastatic Breast Cancer: A Multicenter Retrospective Study from Türkiye

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2026-1-1 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  7. Which patients with colorectal cancer develop brain metastases? A multicenter analysis of clinical and molecular predictors.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.2_suppl.218 Açık erişimli tam metinKaynak: OpenAlex

  8. Unveiling the Uncommon: A Comprehensive Review and Case Report on Targeting Rare MET Fusions in NSCLC

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2025-7-10 Açık erişimli tam metinKaynak: OpenAlex

  9. The Impact of the Systemic Immune-inflammation Index and the Systemic Inflammatory Response Index on Progression-free Survival and Overall Survival in Second-line Immunotherapy for Metastatic Non-small Cell Lung Cancer

    Bagcilar Medical Bulletin, 2026

    DOI 10.4274/bmb.galenos.2026.70299 Açık erişimli tam metinKaynak: OpenAlex

  10. Investigation of Predictive and Prognostic Factors in Metastatic Renal Cell Carcinoma (mRCC) Patients Receiving First-line Treatment: A Retrospective Single-center Experience

    Bagcilar Medical Bulletin, 2026

    DOI 10.4274/bmb.galenos.2026.78942 Açık erişimli tam metinKaynak: OpenAlex

  11. Prognostic Significance and Clinical Implications of the New FIGO 2023 Staging System in Patients with Endometrial Cancer

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15166326 PMID 42652730 Açık erişimli tam metinKaynak: OpenAlex

  12. Clinicopathologic and molecular characteristics of colorectal cancer patients with brain metastases: a multicenter cohort study

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-69206-x Açık erişimli tam metinKaynak: OpenAlex

  13. Prognostic and Predictive Value of Systemic Inflammatory Markers in Epithelial Ovarian Cancer

    Medicina, 2025

    DOI 10.3390/medicina61030380 PMID 40142191 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  14. Clinicopathological Characteristics of Extrapulmonary Neuroendocrine Carcinomas: Treatment Responses and Survival Outcomes: Single-Center Experience

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14072264 PMID 40217714 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  15. The Prognostic and Predictive Roles of Ataxia–Telangiectasia Mutated (ATM) Expression in Patients with Metastatic Non-Small-Cell Lung Cancer Receiving Pembrolizumab Monotherapy Alone or in Combination with Chemotherapy

    Diagnostics, 2025

    DOI 10.3390/diagnostics15081048 PMID 40310425 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  16. Clinical Outcomes in Early-Stage HER2-Low and HER2-Zero Breast Cancer: Single-Center Experience

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14092937 PMID 40363968 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  17. Comparison of Standard Neoadjuvant Therapy and Total Neoadjuvant Therapy in Terms of Effectiveness in Patients Diagnosed with Locally Advanced Rectal Cancer

    Medicina, 2025

    DOI 10.3390/medicina61020340 PMID 40005456 Açık erişimli tam metinKaynak: OpenAlex

  18. Hepatoselüler kanserli hastalarda lokal bölgesel tedaviler ve sorafenib kombinasyonun etkinlik ve güvenilirliği: Tek merkez deneyimi

    Ege Tıp Dergisi, 2025

    DOI 10.19161/etd.1569835 Açık erişimli tam metinKaynak: OpenAlex

  19. Kanserde Takip

    Akademisyen Kitabevi eBooks, 2025

    DOI 10.37609/akya.3716 Açık erişimli tam metinKaynak: OpenAlex

  20. Dirençli Esansiyel Hipertansiyonu Olan Hastalarda Helicobacter pylori Sıklığı ve Helicobacter pylori Eradikasyonunun Kan Basıncı Üzerine Etkisi

    Akademik Gastroenteroloji Dergisi, 2025

    DOI 10.17941/agd.1652762 Kaynak: OpenAlex

  21. The Prognostic Roles of Systemic Inflammatory Markers Before Abiraterone or Enzalutamide Therapy in Metastatic Castration-Resistant Prostate Cancer

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14186536 PMID 41010740 Açık erişimli tam metinKaynak: OpenAlex

  22. Characteristic features and prognostic factors in gastric cancer patients with bone metastases: multicenter experience

    Journal of Chemotherapy, 2024

    DOI 10.1080/1120009x.2024.2358458 PMID 38803194 Kaynak: OpenAlex

  23. Erken Evre Küçük Hücreli Dışı Akciğer Kanserinde Neoadjuvan Tedavilerin Etkinliği: Tek Merkez Deneyimi

    Uludağ Üniversitesi Tıp Fakültesi Dergisi, 2024

    DOI 10.32708/uutfd.1515582 Açık erişimli tam metinKaynak: OpenAlex

  24. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

    Scientific Reports, 2024

    DOI 10.1038/s41598-024-56046-w PMID 38461209 16 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  25. Association Between Baseline and Changes in Early Neutrophil-to-Lymphocyte Ratio on Survival in Patients with Metastatic Bladder Carcinoma Treated with Immunotherapy

    Medicina, 2024

    DOI 10.3390/medicina60122103 PMID 39768982 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  26. Prognostic implications of response to neoadjuvant chemotherapy in breast cancer subtypes

    Journal of Chemotherapy, 2024

    DOI 10.1080/1120009x.2024.2314830 PMID 38351652 2 atıf (Europe PMC) Kaynak: OpenAlex

  27. Kanser Hastalarının Başvurduğu Geleneksel ve Tamamlayıcı Tedaviler - Tıbbi Onkolog Gözü ile Bakış ve Onkolojik İlaçlarla Etkileşim

    Akademisyen Kitabevi eBooks, 2024

    DOI 10.37609/akya.2380 Açık erişimli tam metinKaynak: OpenAlex

  28. Torasik Rayoterapi Sonrası Gelişen Radyasyon Pnömoniti Hastalarında Prognostik ve Prediktif Faktörlerin Analizi: Retrospektif Tek Merkez Deneyimi

    Ege Tıp Bilimleri Dergisi, 2024

    DOI 10.33713/egetbd.1527615 Açık erişimli tam metinKaynak: OpenAlex

  29. Major and minor salivary gland cancers: A multicenter retrospective study

    Head & Neck, 2023

    DOI 10.1002/hed.27376 PMID 37084179 8 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  30. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy

    Medicine, 2023

    DOI 10.1097/md.0000000000033432 PMID 37058061 14 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  31. Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide

    Cancer Chemotherapy and Pharmacology, 2023

    DOI 10.1007/s00280-023-04592-x PMID 37773537 8 atıf (Europe PMC) Kaynak: OpenAlex

  32. Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer

    International Immunopharmacology, 2023

    DOI 10.1016/j.intimp.2023.110947 PMID 37742369 5 atıf (Europe PMC) Kaynak: OpenAlex

  33. The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data

    Journal of Gastrointestinal Cancer, 2023

    DOI 10.1007/s12029-023-00953-0 PMID 37347353 1 atıf (Europe PMC) Kaynak: OpenAlex

  34. The Efficacy And Safety of CDK 4/6 Inhibitors Plus Endocrine Therapy With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2- Negative Metastatic Breast Cancer Patients

    Acta Oncologica Turcica, 2023

    DOI 10.5505/aot.2023.00187 Açık erişimli tam metinKaynak: OpenAlex

  35. Erken Evre Triple Negatif Meme Kanserinde Sağkalım Sonuçları ve Prognostik Faktörler: Tek Merkez Deneyimi

    Uludağ Üniversitesi Tıp Fakültesi Dergisi, 2023

    DOI 10.32708/uutfd.1356458 Açık erişimli tam metinKaynak: OpenAlex

  36. THE IMPORTANCE OF CLINICAL AND LABORATORY PARAMETERS OF BONE MARROW METASTASIS IN PATIENTS WITH SOLID MALIGNANCY-SINGLE CENTER EXPERIENCE

    Karya Journal of Health Science, 2023

    DOI 10.52831/kjhs.1271864 Açık erişimli tam metinKaynak: OpenAlex

  37. CT-guided Transthoracic Lung Biopsy: complications and success in yielding a specific diagnosis

    Annals of Medical Research, 2023

    DOI 10.5455/annalsmedres.2023.11.297 Kaynak: OpenAlex

  38. Impact of systemic inflammatory markers in patients with ALK -positive non-small cell lung cancer treated with crizotinib

    Pulmonology, 2022

    DOI 10.1016/j.pulmoe.2022.11.006 PMID 36564237 13 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  39. Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer

    Journal of Cancer Research and Therapeutics, 2022

    DOI 10.4103/jcrt.jcrt_1104_21 PMID 36510987 6 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  40. The Role of 18F-FDG PET/CT in Predicting the Neoadjuvant Treatment Response in Patients with Locally Advanced Breast Cancer

    Breast Care, 2022

    DOI 10.1159/000524446 PMID 36684400 7 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  41. Gebelikte Onkolojik Yaklaşımlar

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1656 Kaynak: OpenAlex

  42. P40.20 Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients With Metastatic Non-Small Cell Lung Cancer

    Journal of Thoracic Oncology, 2021

    DOI 10.1016/j.jtho.2021.08.457 Açık erişimli tam metinKaynak: OpenAlex

  43. Real-life analysis of immunotherapy as the second or later lines treatment in patients with metastatic non-small cell lung cancer

    Acta Oncologica Turcica, 2021

    DOI 10.5505/aot.2021.26576 Açık erişimli tam metinKaynak: OpenAlex

  44. Platelet to lymphocyte ratio is associated with tumor localization and outcomes in metastatic colorectal cancer

    Medicine, 2021

    DOI 10.1097/md.0000000000027712 PMID 34871263 14 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  45. Prognostic significance of primary tumor localization in patients with metastatic colorectal cancer: Is it beneficial to select targeted treatment? Real-life experience from Turkey.

    PubMed, 2021

    PMID 34761599 Kaynak: OpenAlex

  46. The conversion of RAS status in metastatic colorectal cancer patients after first‐line biological agent treatment

    Colorectal Disease, 2020

    DOI 10.1111/codi.15389 PMID 33002301 3 atıf (Europe PMC) Kaynak: OpenAlex

  47. PROGNOSTIC AND PREDICTIVE MARKERS OF FOLFIRI/AFLIBERCEPT IN PATIENTS WITH METASTATIC COLORECTAL CANCER (TOG STUDY)

    AYBU AVESIS, 2020

    Kaynak: OpenAlex

  48. Triple‐negative breast cancer presented with metastasis to the heart as first sign of recurrence

    The Breast Journal, 2020

    DOI 10.1111/tbj.14091 PMID 33070447 Kaynak: OpenAlex

  49. P1.14-01 Are Pretreatment Inflammation-Based Prognostic Scores Useful in Predicting the Outcomes of Patients with ALK-Positive NSCLC?

    Journal of Thoracic Oncology, 2019

    DOI 10.1016/j.jtho.2019.08.1152 Açık erişimli tam metinKaynak: OpenAlex

  50. P2.01-64 Systemic Inflammatory Markers as a Predictors of Response to Crizotinib in Patients with ALK-Positive Non-Small-Cell Lung Cancer

    Journal of Thoracic Oncology, 2019

    DOI 10.1016/j.jtho.2019.08.1407 Açık erişimli tam metinKaynak: OpenAlex